Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Andrographolide Sulfonate in Community Acquired Pneumonia
NCT02913118Phase 4Unknown
- Sponsor
- Qingfeng Pharmaceutical Group
- Start
- Jul 2016
- Primary completion
- Jan 2019
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in community acquired pneumonia (CAP) comparing AS Injection + Antibiotics with Placebo + Antibiotics (2 arms). Primary endpoints: Time to clinical stability at 14 days and Number of study participants with treatment-related adverse events at 14 days. Status: unknown.
02
Drugs
andrographolide sulfonate
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on NCT02913118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02913118.